Sertraline [(1S,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthyl amine] is a sel... more Sertraline [(1S,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthyl amine] is a selective serotonin reuptake inhibitors (SSRIs). It is considered to be safe, effective and with well-tolerated adverse effects due to its highly specific affinity to central serotonin uptake sites. It has a wide therapeutic range and shows minimal side effects. Sertraline is used therapeutically mainly to treat the symptoms of depression and anxiety. It is also prescribed for the treatment of obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), panic disorder (PD) and social phobia/ anxiety disorder. Sertraline is completely, but slowly, absorbed from the gut with a time to peak plasma concentration (Tmax) of 6-8 h, and undergoes extensive first–pass metabolism by the action of different cytochrome subtypes to form desmethyl-sertraline, an active metabolite with longer half-life. Due to its extensive metabolism and its wide dis...
International Journal of Pharmacy and Pharmaceutical Sciences
Objective: To assess pharmacists’ knowledge with regards registered dietary supplements DS and th... more Objective: To assess pharmacists’ knowledge with regards registered dietary supplements DS and their perception toward DS registration by the ministry of health MOH Methods: A questionnaire was designed to assess pharmacists’ knowledge about newly registered food supplements (registered after 2012) and to assess their view about the current measures followed by MOH in registering these supplements. The questionnaire was distributed to pharmacists in West Bank–Palestine during the period from December 2017 to March 2018. Data collected were analyzed using the Statistical Package for Social Sciences program (SPSS) version 10. Results: Pharmacists’ knowledge with regards to registered DS was high with approximately 86% have recorded the right answers. Their perception about the current increasing registration of DS, pharmacists (67%) thinks that ‘what available DS in the market’ is enough and there is no need for more DS to be registered. Almost half of the pharmacists (48%) think that...
Sertraline [(1S,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthyl amine] is a sel... more Sertraline [(1S,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthyl amine] is a selective serotonin reuptake inhibitors (SSRIs). It is considered to be safe, effective and with well-tolerated adverse effects due to its highly specific affinity to central serotonin uptake sites. It has a wide therapeutic range and shows minimal side effects. Sertraline is used therapeutically mainly to treat the symptoms of depression and anxiety. It is also prescribed for the treatment of obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), panic disorder (PD) and social phobia/ anxiety disorder. Sertraline is completely, but slowly, absorbed from the gut with a time to peak plasma concentration (Tmax) of 6-8 h, and undergoes extensive first–pass metabolism by the action of different cytochrome subtypes to form desmethyl-sertraline, an active metabolite with longer half-life. Due to its extensive metabolism and its wide dis...
International Journal of Pharmacy and Pharmaceutical Sciences
Objective: To assess pharmacists’ knowledge with regards registered dietary supplements DS and th... more Objective: To assess pharmacists’ knowledge with regards registered dietary supplements DS and their perception toward DS registration by the ministry of health MOH Methods: A questionnaire was designed to assess pharmacists’ knowledge about newly registered food supplements (registered after 2012) and to assess their view about the current measures followed by MOH in registering these supplements. The questionnaire was distributed to pharmacists in West Bank–Palestine during the period from December 2017 to March 2018. Data collected were analyzed using the Statistical Package for Social Sciences program (SPSS) version 10. Results: Pharmacists’ knowledge with regards to registered DS was high with approximately 86% have recorded the right answers. Their perception about the current increasing registration of DS, pharmacists (67%) thinks that ‘what available DS in the market’ is enough and there is no need for more DS to be registered. Almost half of the pharmacists (48%) think that...
Uploads